ADVANCED PRIMARY PERITONEAL CARCINOMA
Clinical trials for ADVANCED PRIMARY PERITONEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED PRIMARY PERITONEAL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED PRIMARY PERITONEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
Disease control OngoingThis phase 1 trial tests a combination of the chemotherapy drug gemcitabine and the targeted drug elimusertib in people with advanced pancreatic, ovarian, or other solid tumors that have spread. The goal is to find the safest dose and see whether the combination can shrink or sta…
Matched conditions: ADVANCED PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control OngoingThis trial investigates a new type of immunotherapy for people with advanced cancers that carry a specific marker called NY-ESO-1. Researchers take a patient's own T cells, modify them in the lab to better recognize and attack cancer cells, and then infuse them back. The study al…
Matched conditions: ADVANCED PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Ovarian cancer drug trial aims to unlock DNA secrets before surgery
Knowledge-focused OngoingThis early-phase trial is testing a drug called adavosertib in 38 people with advanced ovarian, fallopian tube, or peritoneal cancer. Participants take the drug for up to 28 days before their scheduled surgery. Researchers will compare tumor DNA before and after treatment to see …
Matched conditions: ADVANCED PRIMARY PERITONEAL CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC